Denosumab
Osteopenia
Amgenmonoclonal_antibodyPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Osteopenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Amg 162 Amgen | Phase 3 | BB |
VITAMIN D University of Erlangen-Nürnberg Medical School | Phase 2 | B |
Lamivudine Philip Grant | Phase 2 | CCC |
Alpha Tocopherol University of Ioannina | N/A | D |
L-AMINO ACIDS University of Ioannina | N/A | D |
Calcium University of Erlangen-Nürnberg Medical School | N/A | D |
Same molecule, other indications
Denosumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →